Another RCT addressed afatinib, which also targets the EGFR pathway (figure 1C), in patients with lung cancer.6 The study included patients with a mutation in the EGFR gene, either deletion 19 or substitution Leu858Arg, genetic alterations that might modify the effect of afatinib. This evidence concerns the gene EGFR and lung carcinoma.